Clinically, the high prevalence of GCGR expression in pNET tissues and its inverse correlation with tumour grade, alongside the reduced GLP-1R expression, point to disrupted insulin–glucagon signalling in tumour progression. The gene discussed is GCGR; the disease is neoplasm.